CL
CPRX

CIM LLC’s Catalyst Pharmaceutical CPRX Stock Holding History

CIM LLC’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-22,556
Closed -$558K – 176
2026
Q1 		$558K Hold
22,556
– – 0.08% 111
2025
Q4 		$526K Sell
22,556
-777
-3% -$17.3K 0.07% 118
2025
Q3 		$460K Hold
23,333
– – 0.06% 127
2025
Q2 		$506K Sell
23,333
-2,511
-10% -$59.3K 0.07% 115
2025
Q1 		$627K Sell
25,844
-1,195
-4% -$26.9K 0.09% 105
2024
Q4 		$564K Sell
27,039
-28
-0.1% -$602 0.08% 115
2024
Q3 		$538K Sell
27,067
-180
-0.7% -$3.34K 0.08% 112
2024
Q2 		$540K Sell
27,247
-104
-0.4% -$1.62K 0.08% 108
2024
Q1 		$436K Buy
27,351
+188
+0.7% +$2.83K 0.07% 111
2023
Q4 		$378K Buy
27,163
+2,250
+9% +$30.8K 0.06% 115
2023
Q3 		$291K Buy
24,913
+871
+4% +$11.7K 0.06% 122
2023
Q2 		$323K Buy
24,042
+1,286
+6% +$18.5K 0.06% 125
2023
Q1 		$377K Sell
22,756
-640
-3% -$10.6K 0.07% 113
2022
Q4 		$362K Sell
23,396
-923
-4% -$14.2K 0.07% 121
2022
Q3 		$340K Buy
+24,319
New +$288K 0.07% 124

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

CIM LLC's CPRX Position: Q2 2026 in Review

CIM LLC sold out of Catalyst Pharmaceutical (CPRX) in Q2 2026, closing a stake of 22,556 shares — an estimated $558K sold.

CIM LLC first reported a position in CPRX in Q3 2022 and held it in 15 quarters. The position peaked at $627K in Q1 2025. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • CIM LLC reported no remaining Catalyst Pharmaceutical position as of Q2 2026 after selling out during the quarter.
  • CIM LLC sold 22,556 Catalyst Pharmaceutical shares in Q2 2026, an estimated $558K.
  • CIM LLC first reported a position in Catalyst Pharmaceutical in Q3 2022 and held it in 15 quarters.
  • CIM LLC's Catalyst Pharmaceutical position peaked at $627K in Q1 2025.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on CIM LLC's 13F filing for Q2 2026, filed 13 Aug 2026.